Fortress Biotech (FRA:CNB1) COGS-to-Revenue : 0.52 (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Fortress Biotech COGS-to-Revenue?

Fortress Biotech's Cost of Goods Sold for the three months ended in Mar. 2024 was €6.27 Mil. Its Revenue for the three months ended in Mar. 2024 was €11.99 Mil.

Fortress Biotech's COGS to Revenue for the three months ended in Mar. 2024 was 0.52.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Fortress Biotech's Gross Margin % for the three months ended in Mar. 2024 was 47.69%.

Fortress Biotech COGS-to-Revenue Historical Data

The historical data trend for Fortress Biotech's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortress Biotech COGS-to-Revenue Chart

Fortress Biotech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.29

0.32

0.47

0.41

0.32

Fortress Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.52	0.45	0.18	0.30	0.52

Fortress Biotech COGS-to-Revenue Calculation

Fortress Biotech's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	24.447	/	77.498
	=	0.32

Fortress Biotech's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	6.271	/	11.988
	=	0.52

Fortress Biotech (FRA:CNB1) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Fortress Biotech's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	6.271 / 11.988
	=	47.69 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Fortress Biotech COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Fortress Biotech's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortress Biotech (FRA:CNB1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortress Biotech Inc (FRA:CNB1) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

FBIOP.PFD:USA FBIO:USA CNB0.PFD:Germany

Address

1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154

Website

https://www.fortressbiotech.com

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors.

Fortress Biotech (FRA:CNB1) Headlines

No Headlines